Mometasone Eg (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. This interaction modifies gene expression, suppressing the production of inflammatory mediators and preventing activation of inflammatory cells, which reduces swelling and mucus in the nose.

The specific dose and frequency of Mometasone Eg are determined by the prescribing clinician based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss any concerns with their doctor.

To request Mometasone Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a potent, once‑daily glucocorticoid with high local anti‑inflammatory activity and minimal systemic absorption compared with some older nasal steroids. Its efficacy in controlling allergic rhinitis and nasal polyps is comparable to fluticasone or budesonide, while offering a convenient dosing schedule.

Mometasone Eg should be stored at room temperature, below 25 °C, in its original packaging. Keep the spray bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

The spray is used intranasally. The patient gently shakes the bottle, primes it if required, tilts the head slightly forward, inserts the tip into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril as directed.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, cataract or glaucoma development, severe allergic reactions such as anaphylaxis, and opportunistic fungal infections of the nasal passages. Patients should report any unusual symptoms promptly.

Mometasone Eg is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery, or those for whom systemic corticosteroid exposure is contraindicated.